EMA Withdrawn: Equidacent (bevacizumab) — Centus Biotherapeutics Europe Limited

View source ↗

Summary

Equidacent (bevacizumab) has been withdrawn from the market in the European Medicines Agency record.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Carcinoma Non-small-cell Lung
• Carcinoma Renal Cell
• Colorectal Neoplasms
• Ovarian Neoplasms

Drugs mentioned

• Equidacent (bevacizumab)

Snippet

Status: Withdrawn. Therapeutic area: Colorectal Neoplasms;Breast Neoplasms;Ovarian Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell. MAH: Centus Biotherapeutics Europe Limited. Decision date: 27/05/2021